BIO Protocol is a decentralized science (DeSci) project designed to accelerate biotechnology innovation. It enables communities of patients, scientists, and biotech professionals to collectively fund, build, and own biotech projects and intellectual property through BioDAOs — decentralized autonomous organizations focused on specific scientific areas. The native token BIO powers this ecosystem, allowing holders to participate in governance, early-stage investment, and liquidity management.
Project History and Milestones
BIO Protocol traces its roots to July 2021 with the launch of VitaDAO, dedicated to longevity research. Key milestones include: August 2021 — first on-chain science funding with the University of Copenhagen; December 2022 — Pfizer Ventures backed VitaDAO in a $4.1 million round; June 2023 — first IP token from Newcastle University; November 2023 — aggregate market cap of BioDAO tokens surpassed $200 million; December 2023 — HairDAO filed the first scientific patent by a DAO; November 2024 — Binance Labs made its first DeSci investment in BIO Protocol; December 2024 — BIO Genesis raised over $33 million. The roadmap includes the launch of BIO Protocol Launchpad and BIO Research Agents in Q1 2025.
BIO Tokenomics
The total supply of BIO at Genesis is 3,320,000,000 tokens with an uncapped maximum supply determined by future governance. Distribution: Community 56% (Community Auction 20%, Airdrop 6%, Ecosystem Incentives 25%); Molecule Ecosystem Fund 5%; Molecule 5%; Investors 13.6%; Core Contributors 21.2%; Advisors 4.2%. The Community Auction portion has 50% unlocked at launch and the remaining 50% vests linearly over one year; the airdrop has a one-year cliff followed by six-year vesting. Current circulating supply is approximately 2.19 billion tokens.
Market Price Performance
As of the latest data, BIO’s all-time high (ATH) is $0.92, with the current price down 96.27% from that peak. Its all-time low (ATL) is $0.02, currently up 116.85% from that low. This extreme volatility reflects high speculation and the early stage of the DeSci sector. BIO is tradable on exchanges such as KuCoin in pre-market and spot markets.
Investment Highlights and Risks
Investing in BIO Protocol offers opportunities to support biotech innovation, gain shared ownership of IP, access early funding rounds, participate in governance, and potentially earn financial returns. However, risks include supply-demand dynamics, project development progress, overall crypto market sentiment, low liquidity, and regulatory uncertainties. The DeSci sector is nascent, and token prices are highly volatile; caution is advised.
Market Impact Analysis
BIO Protocol’s backing by Binance Labs — its first DeSci investment — signals growing mainstream interest in decentralized science. Successful Genesis fundraising and partnerships with pharmaceutical giants like Pfizer set a benchmark for the sector. Yet, the token’s price decline highlights the tension between long-term value and short-term speculation. With the upcoming Launchpad and new BioDAOs, BIO’s ecosystem value may grow, but investors must monitor unlock schedules and potential sell pressure.
In summary, BIO Protocol is a key player in the DeSci landscape, but its token price and long-term value remain subject to market forces. Investors are encouraged to conduct thorough due diligence.